Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals (VNDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 441,455
  • Shares Outstanding, K 59,097
  • Annual Sales, $ 198,770 K
  • Annual Income, $ -18,900 K
  • EBIT $ -114 M
  • EBITDA $ -113 M
  • 60-Month Beta 0.60
  • Price/Sales 2.07
  • Price/Cash Flow N/A
  • Price/Book 0.94

Options Overview Details

View History
  • Implied Volatility 141.11% (+22.38%)
  • Historical Volatility 102.79%
  • IV Percentile 92%
  • IV Rank 37.20%
  • IV High 332.52% on 11/14/25
  • IV Low 27.75% on 09/04/25
  • Expected Move (DTE 33) 2.24 (30.04%)
  • Put/Call Vol Ratio 0.03
  • Today's Volume 2,627
  • Volume Avg (30-Day) 4,028
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 41,891
  • Open Int (30-Day) 32,239
  • Expected Range 5.23 to 9.71

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -2.18
  • Number of Estimates 2
  • High Estimate -2.16
  • Low Estimate -2.19
  • Prior Year -0.08
  • Growth Rate Est. (year over year) -2,625.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.58 +13.53%
on 12/18/25
9.60 -22.19%
on 12/31/25
+0.82 (+12.33%)
since 12/16/25
3-Month
4.27 +74.94%
on 11/07/25
9.60 -22.19%
on 12/31/25
+2.20 (+41.75%)
since 10/16/25
52-Week
3.81 +96.10%
on 05/15/25
9.60 -22.19%
on 12/31/25
+3.03 (+68.24%)
since 01/16/25

Most Recent Stories

More News
Lost Money on Vanda Pharmaceuticals Inc. (VNDA)? Contact Levi & Korsinsky About Fraud Investigation

New York, New York--(Newsfile Corp. - January 15, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Vanda Pharmaceuticals Inc. ("Vanda Pharmaceuticals Inc.") (NASDAQ:...

VNDA : 7.47 (+0.27%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA

NEW YORK , Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ: VNDA). Such investors are...

VNDA : 7.47 (+0.27%)
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder

WASHINGTON , Jan. 8, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has received a decision letter from the U.S. Food and Drug Administration's (FDA)...

VNDA : 7.47 (+0.27%)
Stocks Settle Lower on Tech Weakness and Higher Bond Yields

The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed down -0.74%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.63%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.84%. March...

AMAT : 327.01 (+2.49%)
GOOGL : 330.00 (-0.84%)
AAPL : 255.53 (-1.04%)
B : 48.73 (-1.83%)
HL : 26.54 (+5.23%)
CDE : 22.58 (+6.41%)
$IUXX : 25,529.26 (-0.07%)
ZNH26 : 111-240s (-0.42%)
MSFT : 459.86 (+0.70%)
TSLA : 437.50 (-0.24%)
ESH26 : 6,976.75s (-0.07%)
QCOM : 159.42 (-1.22%)
Stocks Decline as Chip Makers and Data Storage Companies Fall

The S&P 500 Index ($SPX ) (SPY ) today is down -0.33%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.35%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.34%. March E-mini S&P futures...

B : 48.73 (-1.83%)
AVGO : 351.71 (+2.53%)
HL : 26.54 (+5.23%)
$IUXX : 25,529.26 (-0.07%)
ZNH26 : 111-240s (-0.42%)
ESH26 : 6,976.75s (-0.07%)
QCOM : 159.42 (-1.22%)
GFS : 41.24 (-0.70%)
WDC : 221.51 (-0.27%)
$DOWI : 49,359.33 (-0.17%)
SPY : 691.66 (-0.08%)
DIA : 493.42 (-0.18%)
Stocks Slide on Weakness in Megacap Tech Stocks

The S&P 500 Index ($SPX ) (SPY ) today is down -0.15%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.18%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.19%. March E-mini S&P futures...

GOOGL : 330.00 (-0.84%)
AAPL : 255.53 (-1.04%)
HL : 26.54 (+5.23%)
CDE : 22.58 (+6.41%)
$IUXX : 25,529.26 (-0.07%)
ZNH26 : 111-240s (-0.42%)
MSFT : 459.86 (+0.70%)
TSLA : 437.50 (-0.24%)
ESH26 : 6,976.75s (-0.07%)
GFS : 41.24 (-0.70%)
$DOWI : 49,359.33 (-0.17%)
SPY : 691.66 (-0.08%)
Stock Index Futures Slip in Weak End to a Banner Year

March S&P 500 E-Mini futures (ESH26) are down -0.20%, and March Nasdaq 100 E-Mini futures (NQH26) are down -0.32% this morning, pointing to a weak start on Wall Street in the final trading session of 2025....

KLAC : 1,567.82 (+1.48%)
AMAT : 327.01 (+2.49%)
GOOGL : 330.00 (-0.84%)
META : 620.25 (-0.09%)
C : 118.04 (+0.49%)
MOH : 191.40 (-1.21%)
VRTX : 441.36 (+0.56%)
NKE : 64.38 (-0.33%)
SEPL.LN : 326.000 (+2.35%)
ESH26 : 6,976.75s (-0.07%)
ANGH : 3.58 (-2.98%)
NQH26 : 25,689.00s (-0.07%)
Vanda Pharmaceuticals Announces FDA Approval of NEREUSâ„¢ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness

WASHINGTON , Dec. 30, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved NEREUS™ (tradipitant),...

VNDA : 7.47 (+0.27%)
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

WASHINGTON , Dec. 15, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration...

ANAB : 45.68 (-1.36%)
VNDA : 7.47 (+0.27%)
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference

WASHINGTON , Dec. 11, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the J.P. Morgan Healthcare Conference in San Francisco,...

VNDA : 7.47 (+0.27%)

Business Summary

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics...

See More

Key Turning Points

3rd Resistance Point 7.82
2nd Resistance Point 7.68
1st Resistance Point 7.58
Last Price 7.47
1st Support Level 7.34
2nd Support Level 7.20
3rd Support Level 7.10

See More

52-Week High 9.60
Last Price 7.47
Fibonacci 61.8% 7.39
Fibonacci 50% 6.70
Fibonacci 38.2% 6.02
52-Week Low 3.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar